Unmetneeds in the prediction and detection of metastases in prostate cancer

Oliver Sartor, Mario Eisenberger, Michael W. Kattan, Bertrand Tombal, Frederic Lecouvet

Research output: Contribution to journalArticlepeer-review


The therapeutic landscape for the treatment of advanced prostate cancer is rapidly evolving, especially for those patients with metastatic castration-resistant prostate cancer (CPRC). Despite advances in therapy options, the diagnostic landscape has remained relatively static, with few guidelines or reviews addressing the optimal timing or methodology for the radiographic detectionofmetastaticdisease.Givenrecentreportsindicatinga substantial proportion of patients with CRPC thought to be nonmetastatic (M0) are in fact metastatic (M1), there is now a clear opportunity and need for improvement in detection practices. Herein, we discuss the current status of predicting the presence of metastatic disease, with a particular emphasis on the detection of the M0 to M1 transition. In addition, we review current data on newer imaging technologies that are changing the way metastases are detected. Whether earlier detection of metastatic disease will ultimately improve patient outcomes is unknown, but given that the therapeutic options for those with metastatic and nonmetastaticCPRCvary, there are considerable implications ofhowand when metastases are detected.

Original languageEnglish (US)
Pages (from-to)549-557
Number of pages9
Issue number5
StatePublished - May 2013


  • Imaging
  • Lymph nodes
  • Magnetic resonance imaging
  • Neoplasm metastasis
  • Prostatic neoplasms
  • Radionuclide imaging

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Unmetneeds in the prediction and detection of metastases in prostate cancer'. Together they form a unique fingerprint.

Cite this